Indication
Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy.
Loading your page…
Loading your page…
Hepatolenticular Degeneration
Marketing Authorisation Holder: Orphalan
EMA Authorisation: 05/09/2017
INN: trientine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Cuprior: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.